Use of hexokinase-2 in detection of rare tumor cells in body fluid sample and kit
AssigneeSuzhou Junhui Biotechnology Co., Ltd.
InventorsLiu Yang, Yingqi Hua, Zhengdong Cai
Life of this patent
Estimating the term…
Loading patent…
AssigneeSuzhou Junhui Biotechnology Co., Ltd.
InventorsLiu Yang, Yingqi Hua, Zhengdong Cai
Estimating the term…
The present application relates to use of hexokinase-2 and a kit for detecting rare tumor cells in body fluid sample. The present application, based on a principle of abnormal tumor cell energy metabolism, conducts a vitro detection by using a glycolysis marker hexokinase-2 (HK2) as a marker, and assists localization and selection of the rare tumor cells by an addressable microporous array chip or a glass sheet, so as to implement a detection on rare tumor cells having high glycolysis activity in a cancer patient's body fluid sample. The detection method of present application allows to detect rare tumor cells having high glycolysis activity in the human body fluid sample, especially detect circulating tumor cells of an interstitial origin tumor and the circulating tumor cells having epithelial-interstitial transformation in epithelial origin tumors, thereby covering the shortage of traditional detection against the circulating tumor cells based on an epithelial marker, and providing a technical basis for better application of cancer liquid biopsy in clinic.
A method for detecting rare tumor cells in a human body fluid sample, comprising:
A method for detecting rare tumor cells in a human body fluid sample, comprising:
A kit for detecting rare tumor cells, comprising:
A kit for detecting rare tumor cells, comprising:
Use of an anti-HK2 antibody substance in:
Use of an anti-HK2 antibody substance in:
Combined use of a HK2 antibody substance and an epithelial cell marker antibody substance in preparation of a detection kit for identifying CTC characteristics, wherein the HK2 antibody substance is a fluorescein labeled antibody targeting HK2, or a combination of a HK2 antibody with a fluorescein labeled secondary antibody targeting HK2 primary antibody , wherein the epithelial cell marker antibody substance is a fluorescein labeled CK antibody, wherein the CTC characteristics refers to characteristics for distinguishing CTC cells as epithelial origin tumor cells, tumor cells having epithelial-interstitial transformation, or tumor cells of interstitial origin, wherein the kit comprises a fluorescein labeled antibody targeting the leukocyte marker, a cell nucleus stain, and an instruction recording:
Combined use of a HK2 antibody substance and an epithelial cell marker antibody substance in preparation of a detection kit for identifying CTC characteristics, wherein the HK2 antibody substance is a fluorescein labeled antibody targeting HK2, or a combination of a HK2 antibody with a fluorescein labeled secondary antibody targeting HK2 primary antibody , wherein the epithelial cell marker antibody substance is a fluorescein labeled CK antibody, wherein the CTC characteristics refers to characteristics for distinguishing CTC cells as epithelial origin tumor cells, tumor cells having epithelial-interstitial transformation, or tumor cells of interstitial origin, wherein the kit comprises a fluorescein labeled antibody targeting the leukocyte marker, a cell nucleus stain, and an instruction recording:
Dependencies are inferred from the claim text.